Biohaven Ltd. (BHVN)

Biohaven Ltd. (BHVN) is a Biotechnology company in the Healthcare sector listed on the NYSE.

As of Oct 23, 2026: market cap $1.8B; returns 1 day -5.5%, 1 week +28.8%, 1 year -14.8%.

Biohaven is a clinical-stage biopharmaceutical company that re-launched following the 2022 acquisition of its successful CGRP migraine franchise, including the blockbuster drug NURTEC® ODT (rimegepant), by Pfizer for $11.6 billion. The current iteration of Biohaven, led by the same management team, is focused on developing a diverse pipeline of therapies for neurological and rare diseases.

Groups BHVN belongs to

• Biotechnology
• Biopharmaceutical
• Clinical Stage
• Clinical Stage Biotech
• Neuroscience
• Neurological Disorders
• Rare Diseases
• Epilepsy
• Metabolic Disorders
• Weight Management
• Healthcare
• Drug Discovery

BHVN financial model: income statement, cash flow and balance sheet